That this House welcomes the decision by the National Institute for Health and Care Excellence (NICE) to recommend dinutuximab beta for the treatment of children with high-risk neuroblastoma; praises the collaborative and flexible approach of all parties including NICE, EUSA Pharma, Solving Kids' Cancer, Neuroblastoma UK, the Children's Cancer and Leukaemia group, JACK, the Bradley Lowery Foundation, Hugs from Henry, Christopher's Smile, Niamh's Next Steps and Smile with Siddy, Grace Kelly Ladybird Trust, Rupert's Revenge Trust, Stacey's Smiles, Harvey Hext Trust, George and the Giant Pledge and Abbie's Army; notes the dedication and involvement of the clinical community in supporting the appraisal process; and calls on the House to praise the bravery of all those children suffering from high-risk neuroblastoma in the UK today.

That this House welcomes the decision by the National Institute for Health and Care Excellence (NICE) to recommend dinutuximab beta for the treatment of children with high-risk neuroblastoma; praises the collaborative and flexible approach of all parties including NICE, EUSA Pharma, Solving Kids' Cancer, Neuroblastoma UK, the Children's Cancer and...

That this House commends the efforts of the Cystic Fibrosis Trust in campaigning for access to the precision medicine Orkambi; recognises that the campaign has been ongoing for nearly three years; further recognises the urgency of the situation as every month that passes is critical for people with cystic fibrosis; welcomes the negotiations between the NHS and Vertex; and calls on the Government to urgently intervene to help secure a timely resolution to ensure an agreement is reached that will enable patient access to the drug without further delay.

That this House commends the efforts of the Cystic Fibrosis Trust in campaigning for access to the precision medicine Orkambi; recognises that the campaign has been ongoing for nearly three years; further recognises the urgency of the situation as every month that passes is critical for people with cystic fibrosis;...

That this House notes that March is Brain Tumour Awareness Month across the UK; congratulates all brain tumours charities and their supporters for their activities to raise awareness of the disease; recognises that brain tumours are the biggest cancer killer of children and adults under 40; congratulates The Brain Tumour Charity on its excellent work funding pioneering research to raise awareness of the symptoms and effects of brain tumours; commends their UK-wide HeadSmart campaign which educates the public and healthcare professionals about the signs and symptoms of childhood brain tumours; encourages parliamentarians to support Brain Tumour Awareness Month; and urges the Government to take action to help deliver long-overdue improvements in brain tumour awareness, diagnosis, treatment, care and research.

That this House notes that March is Brain Tumour Awareness Month across the UK; congratulates all brain tumours charities and their supporters for their activities to raise awareness of the disease; recognises that brain tumours are the biggest cancer killer of children and adults under 40; congratulates The Brain Tumour...

That this House notes the difficulty faced by disabled people who are unable to use standard accessible toilets in public places; understands the impact this has on the ability of many people to carry out day-to-day tasks outside of the home; is aware that Changing Places toilets would enable over 250,000 people to get out and about and carry out day-to-day activities; further notes that this would affect the daily lives of people with profound and multiple learning difficulties, motor neurone disease, multiple sclerosis and cerebral palsy; notes the petition to Change Building and Planning Regulations to Make Changing Places Toilets Compulsory, recently submitted to the Prime Minister, and the support of over 52,000 signatories for it; and urges the Government to act on the clear public support to ensure that Changing Places facilities are built into all new public buildings.

That this House notes the difficulty faced by disabled people who are unable to use standard accessible toilets in public places; understands the impact this has on the ability of many people to carry out day-to-day tasks outside of the home; is aware that Changing Places toilets would enable over...

That this House calls on the Government to acknowledge that 50 is the internationally-recognised optimal age at which bowel cancer screening should begin; further calls for a commitment from the Government to reduce the age for bowel cancer screening from 60 to 50 in England to bring policy in line with Scotland, and for the devolved administrations in Wales and Northern Ireland to also follow suit; notes that bowel cancer is the UK's second biggest cancer killer and that around 41,000 people are diagnosed with bowel cancer each year, more than one in 10 of whom are in their 50s; further notes that being diagnosed early, stage 1, offers a 97 per cent survival rate, while being diagnosed late, stage 4, carries a survival rate of just seven per cent; notes the online petition in support of lowering the screening age to 50 on Change.org which has gathered the support of over 375,000 people, and counting; and welcomes the recommendation from the National Institute for Health and Care Excellence that the FIT test should be used to guide referral of possible bowel cancer patients, giving GPs a clear alternative to endoscopy as a first line of investigation and potentially delivering substantial cost-savings.

That this House calls on the Government to acknowledge that 50 is the internationally-recognised optimal age at which bowel cancer screening should begin; further calls for a commitment from the Government to reduce the age for bowel cancer screening from 60 to 50 in England to bring policy in line...

That this House recognises hepatitis C is a leading cause of premature death from liver disease; acknowledges that the condition is curable in most cases; understands that there are inequalities in access to treatment and diagnosis for people in disadvantaged groups; notes that recent data has revealed that the UK is falling behind targets to meet its commitment to eliminating hepatitis C as a public health concern by 2030; further notes that the reduction in price of new HCV oral therapies puts the NHS in a position to work innovatively with industry to look at how it can find and treat more patients and faster; notes a recent article in the Lancet which states that domestic funding is unlikely to be able to deliver the results in the 13 years that remain till 2030; and calls on the NHS to bring forward the publication of an elimination strategy for the UK, which includes innovative, long-term activities with industry, stakeholders and community-based organisations across the health sector.

That this House recognises hepatitis C is a leading cause of premature death from liver disease; acknowledges that the condition is curable in most cases; understands that there are inequalities in access to treatment and diagnosis for people in disadvantaged groups; notes that recent data has revealed that the UK...

That this House supports World Diabetes Day on 4 November 2017 when millions of people around the world come together to raise awareness of diabetes; congratulates the International Diabetes Federation for running this annual campaign; and commends those who have helped make the blue light challenge a success where monuments and local landmarks in areas across the country turn blue in support of this day in particular the Trafalgar Square Fountain, top floor of City Hall, London, the Olympic Stadium, London, Manchester Town Hall, the candlestick and a harbour light in Whitehaven, Cumbrian, One Canada Square, London, St Mary's Lighthouse, North Tyneside, with the cities Liverpool and Leicester along with many others nationwide.

That this House supports World Diabetes Day on 4 November 2017 when millions of people around the world come together to raise awareness of diabetes; congratulates the International Diabetes Federation for running this annual campaign; and commends those who have helped make the blue light challenge a success where monuments...

That this House notes that out of the estimated 31,500 children and young people with diabetes under the age of 19, about 1.9 per cent have type 2 diabetes which is linked to lifestyle choice; and calls on the Government to publish its Childhood Obesity Strategy to help make it easier for children and their families make healthier choices.

That this House notes that out of the estimated 31,500 children and young people with diabetes under the age of 19, about 1.9 per cent have type 2 diabetes which is linked to lifestyle choice; and calls on the Government to publish its Childhood Obesity Strategy to help make it...

That this House congratulates NICE on recommending that all UK citizens over the age of 40 should receive a diabetes check; notes that more than 500,000 people are thought to be living with undiagnosed diabetes; further notes type 2 diabetes is reversible with the right support; and calls on those in the medical profession and the Government to support this recommendation and make it a reality.

That this House congratulates NICE on recommending that all UK citizens over the age of 40 should receive a diabetes check; notes that more than 500,000 people are thought to be living with undiagnosed diabetes; further notes type 2 diabetes is reversible with the right support; and calls on those...

That this House notes the decision by NICE to stop the availability of the drug anakinra for patients who have been diagnosed with the rare condition Tumour Necrosis Factor Receptor Periodic Syndrome after March 2016; further notes that the decision was to allow the use of anakinra in exceptional circumstances; believes that the case of Harriet North from Morecambe and Lunesdale is an exceptional circumstance as it is one of the worst cases of the illness in the 70 cases in the county; and urges NHS England to reconsider their decision and to allow Harriet to be prescribed anakinra to not only improve her quality of life but extend her life.

That this House notes the decision by NICE to stop the availability of the drug anakinra for patients who have been diagnosed with the rare condition Tumour Necrosis Factor Receptor Periodic Syndrome after March 2016; further notes that the decision was to allow the use of anakinra in exceptional circumstances;...

That this House notes the growing concern from medical professionals and clinical experts regarding the lack of comprehensive care for people suffering from chronic pain and, in some cases, the harmful and unhelpful purchases of repeated over-the-counter opioids to treat them; observes that 40 per cent of British adults surveyed by the Chronic Pain Policy Coalition have taken opioid painkillers consecutively for three days or longer, despite NICE guidelines recommending that they should be taken for three days as a maximum; understands that there is a lack of awareness regarding the addictive quality of opioids, alternative treatments and the effect on mental health of poorly-managed chronic pain, including depression and anxiety; and calls on the Government to work with GPs, clinical commissioning groups and key stakeholder groups to increase the number of people receiving annual checks as well as care plans which will reduce avoidable GP appointments, visits to accident and emergency departments and prescription charges.

That this House notes the growing concern from medical professionals and clinical experts regarding the lack of comprehensive care for people suffering from chronic pain and, in some cases, the harmful and unhelpful purchases of repeated over-the-counter opioids to treat them; observes that 40 per cent of British adults surveyed...

That this House notes that NICE has failed to approve the anti-cancer drug Nivolumab for use in England, whereas the drug is already being prescribed in Scotland; further notes that Nivolumab is known as the wonder drug by many clinicians due to its success; congratulates Terri Robson of Leyton and her family and supporters for raising more than 170,000 signatures on a petition calling for Nivolumab to be prescribed in England; and calls on NICE to review urgently its decision for the sake of thousands of patients who are desperately in need of Nivolumab.

That this House notes that NICE has failed to approve the anti-cancer drug Nivolumab for use in England, whereas the drug is already being prescribed in Scotland; further notes that Nivolumab is known as the wonder drug by many clinicians due to its success; congratulates Terri Robson of Leyton and...

That this House notes that 15 to 21 May 2016 is National Epilepsy Week, and congratulates the work of SUDEP Action and other charities to raise awareness, promote research and provide information and support for those affected by the condition; further notes with concern that people with epilepsy are 11 times more likely to die prematurely than people without the condition, that many deaths are potentially avoidable, are in the young and that there have been 14,926 reported deaths since governments across the UK pledged to take action to save lives following SUDEP Action's National Audit of Epilepsy Deaths in 2002; congratulates Cornwall NHS Foundation Trust, Plymouth University, SUDEP Action and Cornwall Royal Hospital on winning the BMJ Neurology Team of the Year Award for enhanced patient safety in epilepsy for an innovative approach to tackling mortality; acknowledges the fall in the number of epilepsy-related deaths in Cornwall, with no deaths reported in the community-based learning disability service in the last five years; urges NHS England to support the dissemination of best practice across the country and the signposting of families to SUDEP Action after a death; commends innovative approaches to self-monitoring and the management of risk factors, such as the SUDEP and Seizure Safety Checklist and EpSMon, the self-monitor app; further acknowledges the Government's duty to do everything it can to improve standards of epilepsy care and take action so that lives can be saved; and therefore calls on the Government to work closely with all national epilepsy charities towards achieving this goal.

That this House notes that 15 to 21 May 2016 is National Epilepsy Week, and congratulates the work of SUDEP Action and other charities to raise awareness, promote research and provide information and support for those affected by the condition; further notes with concern that people with epilepsy are 11...

That this House welcomes the announcement by Boots that it intends to offer in-store diabetes treatments; acknowledges that pharmacists carrying out diabetes treatments will reduce patient delays and reduce GP waiting times; notes that 80 per cent of NHS spending on diabetes is on avoidable complications and that this could be reduced by easily accessible and prompt treatment; further notes that community pharmacies are facing cuts of £170 million which could see 3,000 out of 11,674 pharmacies close; and urges the Government to mitigate these cuts by utilising community pharmacies to provide free services to patients and relieve pressure on the NHS.

That this House welcomes the announcement by Boots that it intends to offer in-store diabetes treatments; acknowledges that pharmacists carrying out diabetes treatments will reduce patient delays and reduce GP waiting times; notes that 80 per cent of NHS spending on diabetes is on avoidable complications and that this could...

That this House notes that Parkinson's awareness week offers the opportunity for the wider community to become more knowledgeable about those having to deal with the condition; commends the tens of thousands of carers, families and volunteers for Parkinson's UK who are raising millions for the charity on a regular basis; and notes that some of these volunteers, despite suffering from the condition themselves, still continue their work over periods spanning many years.

That this House notes that Parkinson's awareness week offers the opportunity for the wider community to become more knowledgeable about those having to deal with the condition; commends the tens of thousands of carers, families and volunteers for Parkinson's UK who are raising millions for the charity on a regular...

That this House welcomes the decision by the National Institute for Health and Care Excellence (NICE) to recommend the Duchenne muscular dystrophy treatment, Translarna, for funding by NHS England, as a result of a Managed Access Agreement; notes that Translarna is the first ever approved drug to treat an underlying genetic cause of Duchenne muscular dystrophy; recognises the tireless campaigning by patients and families throughout the NHS England and NICE processes calling for access to Translarna; acknowledges the vital role that Muscular Dystrophy UK and Action Duchenne have played as patient organisation stakeholders during the NICE assessment process; further recognises the role of other charities in pressing for access to Translarna; further notes with concern the announcement by the Scottish Medicines Consortium to recommend that Translarna not be approved for funding by NHS Scotland; and calls on NHS England to shorten implementation from three months so that the drug is available as quickly as possible.

That this House welcomes the decision by the National Institute for Health and Care Excellence (NICE) to recommend the Duchenne muscular dystrophy treatment, Translarna, for funding by NHS England, as a result of a Managed Access Agreement; notes that Translarna is the first ever approved drug to treat an underlying...

That this House notes continued efforts by the scientific community to find a cure for Parkinson's disease, including new and experimental efforts to advance research; and reaffirms its commitment to give full support where appropriate to those trying to find a cure for the disease.

That this House notes continued efforts by the scientific community to find a cure for Parkinson's disease, including new and experimental efforts to advance research; and reaffirms its commitment to give full support where appropriate to those trying to find a cure for the disease.